Evidence map›Paper›PMID 41369552›Full record

ArticleJournal of virology2026

A small-molecule HSP90 inhibitor, NVP-HSP990, alleviates rotavirus infection.

Yi Cao, Qingmin Zhu, Xiaoping Wu, Zhunyi Xie, Chengying Yang, Yanyan Guo, Dongwei Meng, Xinyuan Zhou, Yuzhang Wu, Jintao Li and 1 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi Cao *Department of Immunology, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.
Qingmin Zhu *Team 13 of the Fourth Brigade, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.
Xiaoping WuInstitute for Cancer Medicine and School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China.
Zhunyi XieDepartment of Immunology, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.
Chengying YangDepartment of Immunology, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.
Yanyan GuoDepartment of Immunology, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.
Dongwei MengDepartment of Immunology, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.
Xinyuan ZhouDepartment of Immunology, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.
Yuzhang WuDepartment of Immunology, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.
Jintao LiDepartment of Biosafety, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.ORCID 0000-0003-3637-2386
Haiyang HeDepartment of Immunology, Basic Medical School, Army Medical University (Third Military Medical University), Chongqing, China.ORCID 0000-0002-3210-1610

Funding

Chongqing Municipal Basic and Frontier Research Project cstc2015jcyjBX0086National Natural Science Foundation of China 32070884National Natural Science Foundation of China 81570497
6 · The paper itself

Abstract

Rotavirus (RV) infection remains a leading cause of hospitalization and mortality among infants and young children. Despite global implementation of RV vaccines, hundreds of thousands of infants and young children still succumb to this disease each year due to ineffective treatment. In this study, we demonstrated that NVP-HSP990, a novel small-molecule heat shock protein 90 (HSP90) inhibitor, inhibited RV infection with a fascinatingly higher selectivity index compared to conventional HSP90 inhibitors like geldanamycin and its derivative tanespimycin (17-allylamino-17-demethoxygeldanamycin [17-AAG]). NVP-HSP990 effectively inhibited RV replication

Indexed as

Antiviral AgentsHSP90 Heat-Shock ProteinsRotavirusRotavirus InfectionsAnimalsBenzoquinonesCaco-2 CellsDisease Models, AnimalHumansLactams, MacrocyclicMiceMice, Inbred BALB CVirus ReplicationAntiviral AgentsBenzoquinonesHSP90 Heat-Shock ProteinsLactams, MacrocyclicdiarrheaMAPK signaling pathwayNVP-HSP990rotavirustight junctions

Identifiers

PMID41369552
PMCPMC12817916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.